In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled important changes regarding a number of tests we perform. Listed below are the types of changes that may be included in this notification, effective Monday, March 05, 2012

**New Tests** - Tests recently added to the NMS Labs test menu.  *New Tests are effective immediately.*

**Test Changes** - Tests that have had changes to the method/ CPT code, units of measurement, scope of analysis, reference comments, or specimen requirements.

**Discontinued Tests** - Tests being discontinued with alternate testing suggestions.

Please use this information to update your computer systems/records. These changes are important to ensure standardization of our mutual laboratory databases.

If you have any questions about the information contained in this notification, please call our Client Support Department at (866) 522-2206. Thank you for your continued support of NMS Labs and your assistance in implementing these changes.

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. NMS Labs does not assume responsibility for billing errors due to reliance on the CPT Codes listed in this document.
<table>
<thead>
<tr>
<th>Test Code</th>
<th>Test Name</th>
<th>New Test</th>
<th>Test Name</th>
<th>Method / CPT Code</th>
<th>Specimen Req.</th>
<th>Stability</th>
<th>Scope</th>
<th>Units</th>
<th>Reference Comments</th>
<th>Discontinue</th>
</tr>
</thead>
<tbody>
<tr>
<td>8890OF</td>
<td>Amphetamines Panel (Qualitative), Oral Fluids</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0478FL</td>
<td>Astemizole and Metabolite, Fluid</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0478SP</td>
<td>Astemizole and Metabolite, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0478TI</td>
<td>Astemizole and Metabolite, Tissue</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8891OF</td>
<td>Benzodiazepines Panel (Qualitative), Oral Fluids</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1140P</td>
<td>Chloroquine, Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1140SP</td>
<td>Chloroquine, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8893OF</td>
<td>Cocaine and Metabolites (Qualitative), Oral Fluids</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8892OF</td>
<td>Delta-9 THC (Qualitative), Oral Fluids</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2526B</td>
<td>Leflunomide as Metabolite, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2543B</td>
<td>Lurasidone, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2543SP</td>
<td>Lurasidone, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8894OF</td>
<td>Methadone and Metabolite (Qualitative), Oral Fluids</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8602B</td>
<td>Methamphetamine and Metabolite, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8602FL</td>
<td>Methamphetamine and Metabolite, Fluid</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8602SP</td>
<td>Methamphetamine and Metabolite, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8602TI</td>
<td>Methamphetamine and Metabolite, Tissue</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2810U</td>
<td>Methamphetamine and Metabolite, Urine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8895OF</td>
<td>Opiates (Qualitative), Oral Fluids</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8896OF</td>
<td>Phencyclidine and Dextromethorphan (Qualitative), Oral Fluids</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4030B</td>
<td>Pyridine, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4030SP</td>
<td>Pyridine, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4030U</td>
<td>Pyridine, Urine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4790B</td>
<td>Vilazodone, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4790SP</td>
<td>Vilazodone, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
New Tests

8890OF Amphetamines Panel (Qualitative), Oral Fluids Effective Immediately

Scope of Analysis: Amphetamine [LC-MS/MS], MDA [LC-MS/MS], MDMA [LC-MS/MS], Methamphetamine [LC-MS/MS]
Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose: Identification by LC-MS/MS
Category: Stimulant, Stimulant, Anorexogenic

Specimen Requirements:
Minimum Volume: 1 mL Oral Fluid
Special Handling: Use either an OraSure Intercept® or Immunalysis QuantisalTM collection device and follow the manufacturer's directions. It is recommended that samples be submitted in the original collection device. However, pour-off containers will be accepted. Samples are stable up to 3 days at room temperature and should be refrigerated thereafter. DO NOT FREEZE the OraSure Intercept® or Immunalysis QuantisalTM collection devices.
Specimen Container: Oral Fluid collection device
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: None
Stability: Room Temperature: Undetermined
Refrigerated: 21 day(s)
Frozen (-20 °C): Undetermined

**Method:** High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Thursday 2 days (after set-up)
CPT Code: 83788

<table>
<thead>
<tr>
<th>Compound Name / Alias</th>
<th>Units</th>
<th>RL</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amphetamine</td>
<td>ng/mL</td>
<td>10</td>
<td>Amphetamine (Adderall, Dexedrine) is a Schedule II phenethylamine CNS-stimulant. It is used therapeutically in the treatment of narcolepsy and obesity and also in the treatment of attention deficit/hyperactivity disorder. Amphetamine has a high potential for abuse and dependence.</td>
</tr>
<tr>
<td>Methamphetamine</td>
<td>ng/mL</td>
<td>10</td>
<td>d-Methamphetamine (Desoxyn) is a DEA schedule II stimulant drug, subject to abuse and dependence. Chemically, there are two forms (isomers) of methamphetamine: l- and d-methamphetamine. This test does not distinguish between these two isomers.</td>
</tr>
<tr>
<td>MDA Adam; Methyleneoxyamphetamine</td>
<td>ng/mL</td>
<td>10</td>
<td>3,4-Methylenedioxyamphetamine (MDA) is an amphetamine derivative and a chemical analogue and metabolite of 3,4-methylenedioxyamphetamine (MDMA). This compound is abused for its central nervous system stimulant and hallucinogenic properties.</td>
</tr>
<tr>
<td>MDMA Ecstasy; Methyleneoxymethamphetamine</td>
<td>ng/mL</td>
<td>10</td>
<td>3,4-Methylenedioxyamphetamine (MDMA, Ecstasy) is a DEA Schedule I controlled substance and is a synthetic sympathomimetic compound with mixed stimulant, psychotropic, and hallucinogenic activities. This compound is abused for its central nervous system stimulant and hallucinogenic properties.</td>
</tr>
</tbody>
</table>
**New Tests and Test Updates**

**Effective Date:**
Monday, March 05, 2012

**New Tests**

<table>
<thead>
<tr>
<th>8891OF</th>
<th>Benzodiazepines Panel (Qualitative), Oral Fluids</th>
<th>Effective Immediately</th>
</tr>
</thead>
</table>

Scope of Analysis: Alprazolam [LC-MS/MS], Chlordiazepoxide [LC-MS/MS], Clonazepam [LC-MS/MS], Diazepam [LC-MS/MS], Lorazepam [LC-MS/MS], Midazolam [LC-MS/MS], Nordiazepam [LC-MS/MS], Oxazepam [LC-MS/MS], Temazepam [LC-MS/MS]

Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Purpose: Identification by LC-MS/MS

Category: Anxiolytic, Sedative, Anticonvulsant

Specimen Requirements: 1 mL Oral Fluid

Minimum Volume: 0.7 mL

Special Handling: Use either an OraSure Intercept® or Immunalysis QuantisalTM collection device and follow the manufacturer's directions. It is recommended that samples be submitted in the original collection device. However, pour-off containers will be accepted. Samples are stable up to 3 days at room temperature and should be refrigerated thereafter. DO NOT FREEZE the OraSure Intercept® or Immunalysis QuantisalTM collection devices.

Specimen Container: Oral Fluid collection device

Transport Temperature: Refrigerated

Light Protection: Not Required

Rejection Criteria: None

Stability: Room Temperature: Undetermined

Refrigerated: 21 day(s)

Frozen (-20 °C): Undetermined

**Method:** High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Thursday 2 days (after set-up)

CPT Code: 83788

<table>
<thead>
<tr>
<th>Compound Name / Alias</th>
<th>Units</th>
<th>RL</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diazepam (Valium)</td>
<td>ng/mL</td>
<td>6.0</td>
<td>Diazepam (Valium) is a schedule IV benzodiazepine used primarily for its sedative, anxiolytic, anticonvulsant, or muscle relaxing effects, and is a CNS depressant.</td>
</tr>
<tr>
<td>Nordiazepam</td>
<td>ng/mL</td>
<td>6.0</td>
<td>Nordiazepam is a pharmacologically active metabolite of several benzodiazepine anxiolytic/sedative/hypnotic agents including diazepam.</td>
</tr>
<tr>
<td>Oxazepam (Serax®)</td>
<td>ng/mL</td>
<td>9.0</td>
<td>Oxazepam is a DEA schedule IV benzodiazepine with CNS depressant properties. It is frequently seen as the metabolite of diazepam and other benzodiazepines.</td>
</tr>
<tr>
<td>Temazepam (Normison®, Restoril®)</td>
<td>ng/mL</td>
<td>6.0</td>
<td>Temazepam (Restoril) is a DEA schedule IV benzodiazepine hypnotic agent used in the short-term relief of insomnia. It has CNS depressant properties. Temazepam is also a metabolite of diazepam (Valium).</td>
</tr>
<tr>
<td>Chlordiazepoxide (Librium®)</td>
<td>ng/mL</td>
<td>100</td>
<td>Chlordiazepoxide (Librium) is a benzodiazepine with CNS depressant properties used for the management of anxiety and for aid in alcohol withdrawal.</td>
</tr>
<tr>
<td>Lorazepam (Ativan®)</td>
<td>ng/mL</td>
<td>6.0</td>
<td>Lorazepam (Ativan) is a DEA Schedule IV benzodiazepine with CNS depressant properties, used in the treatment of anxiety and for short-term relief of anxiety associated with depressive symptoms.</td>
</tr>
<tr>
<td>Clonazepam (Klonopin®)</td>
<td>ng/mL</td>
<td>6.0</td>
<td>Clonazepam (Klonopin) is a DEA Schedule IV benzodiazepine-derivative anticonvulsant agent with CNS depressant properties. It is used in both the prophylaxis and treatment of various seizure disorders.</td>
</tr>
<tr>
<td>Alprazolam (Xanax®)</td>
<td>ng/mL</td>
<td>6.0</td>
<td>Alprazolam (Xanax) is a DEA Schedule IV second-generation benzodiazepine with CNS depressant properties. It is effective at low doses, and is used in the management of anxiety disorders.</td>
</tr>
</tbody>
</table>
### New Tests

#### Compound Name / Alias

<table>
<thead>
<tr>
<th>Compound Name / Alias</th>
<th>Units</th>
<th>RL</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Midazolam / Versed®</td>
<td>ng/mL</td>
<td>9.0</td>
<td>Midazolam (Versed) is a DEA schedule IV short acting benzodiazepine with strong central nervous system depressant/hypnotic properties.</td>
</tr>
</tbody>
</table>

#### 1140P Chloroquine, Plasma

**Effective Immediately**

**Scope of Analysis:** Chloroquine [LC-MS/MS]

**Method(s):** High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

**Purpose:** Therapeutic Drug Monitoring

**Category:** Antimalarial

**Specimen Requirements:** 1 mL Plasma

**Minimum Volume:** 0.4 mL

**Special Handling:** Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Plasma into a plastic screw capped vial using approved guidelines.

**Specimen Container:** Plastic container (preservative-free)

**Transport Temperature:** Refrigerated

**Light Protection:** Not Required

**Rejection Criteria:** Polymer gel separation tube (SST or PST).

**Stability:**
- Room Temperature: 30 day(s)
- Refrigerated: 30 day(s)
- Frozen (-20 °C): 30 day(s)

**Method:** High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

**Set-Up Days / TAT:** Tuesday 3 days (after set-up)

**CPT Code:** 83789

**Compound Name / Alias**

<table>
<thead>
<tr>
<th>Compound Name / Alias</th>
<th>Units</th>
<th>RL</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chloroquine Aralen®; Reumachlor®</td>
<td>ng/mL</td>
<td>10</td>
<td>Eleven adults given an infused 300 mg dose developed peak plasma chloroquine concentrations averaging 840 ng/mL. Ten pediatric malaria patients given a 10 mg/kg initial dose with an additional 5 mg/kg every 12 hours had peak plasma concentrations of 250 +/- 30 ng/mL at approximately 2 hours.</td>
</tr>
</tbody>
</table>

#### 8893OF Cocaine and Metabolites (Qualitative), Oral Fluids

**Effective Immediately**

**Scope of Analysis:** Benzylecgonine [LC-MS/MS], Cocaethylene [LC-MS/MS], Cocaine [LC-MS/MS]

**Method(s):** High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

**Purpose:** Identification by LC-MS/MS

**Category:** Stimulant

**Specimen Requirements:** 1 mL Oral Fluid

**Minimum Volume:** 0.7 mL

**Special Handling:** Use either an OraSure Intercept® or Immunalysis QuantisalTM collection device and follow the manufacturer's directions. It is recommended that samples be submitted in the original collection device. However, pour-off containers will be accepted. Samples are stable up to 3 days at room temperature and should be refrigerated thereafter. DO NOT FREEZE the OraSure Intercept® or Immunalysis QuantisalTM collection devices.

**Specimen Container:** Oral Fluid collection device
New Tests

Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: None

Stability:
- Room Temperature: Undetermined
- Refrigerated: 21 day(s)
- Frozen (-20 °C): Undetermined

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

<table>
<thead>
<tr>
<th>Compound Name / Alias</th>
<th>Units</th>
<th>RL</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cocaine</td>
<td>ng/mL</td>
<td>10</td>
<td>Cocaine is a DEA Schedule II controlled central nervous stimulant drug. Cocaine has a high potential for abuse and dependence.</td>
</tr>
<tr>
<td>Benzoylcegonine</td>
<td>ng/mL</td>
<td>6.0</td>
<td>Benzoylcegonine is an inactive metabolite and chemical breakdown product of cocaine. Cocaine is a DEA Schedule II controlled central nervous stimulant drug. Cocaine has a high potential for abuse and dependence.</td>
</tr>
<tr>
<td>Cocaethylene</td>
<td>ng/mL</td>
<td>6.0</td>
<td>Cocaethylene is a transesterification artifact formed in vivo when cocaine and alcohol are taken together. It is an active metabolite of cocaine.</td>
</tr>
</tbody>
</table>

8892OF Delta-9 THC (Qualitative), Oral Fluids

Scope of Analysis: Delta-9 THC [GC/MS]
Method(s): Gas Chromatography/Mass Spectrometry (GC/MS)
Purpose: Identification by GC/MS
Category: Hallucinogen

Specimen Requirements:
- Minimum Volume: 1 mL Oral Fluid
- Special Handling: Use either an OraSure Intercept® or Immunalysis QuantisalTM collection device and follow the manufacturer's directions. It is recommended that samples be submitted in the original collection device. However, pour-off containers will be accepted. Samples are stable up to 3 days at room temperature and should be refrigerated thereafter. DO NOT FREEZE the OraSure Intercept® or Immunalysis QuantisalTM collection devices.

Specimen Container: Oral Fluid collection device
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: None
Stability:
- Room Temperature: Undetermined
- Refrigerated: 21 day(s)
- Frozen (-20 °C): Undetermined

Method: Gas Chromatography/Mass Spectrometry (GC/MS)

<table>
<thead>
<tr>
<th>Compound Name / Alias</th>
<th>Units</th>
<th>RL</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delta-9 THC</td>
<td>ng/mL</td>
<td>2.0</td>
<td>Delta-9-THC is the active component in marijuana. Marijuana is a DEA Schedule I hallucinogen. THC may persist in the oral cavity for several hours following smoking of marijuana.</td>
</tr>
</tbody>
</table>
New Tests

2543B  Lurasidone, Blood  Effective Immediately

Scope of Analysis:  Lurasidone [LC-MS/MS]
Method(s):  High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:  Therapeutic Drug Monitoring
Category:  Antipsychotic

Specimen Requirements:  1 mL Blood
Minimum Volume:  0.3 mL
Special Handling:  None
Specimen Container:  Gray top tube (Sodium Fluoride / Potassium Oxalate)
Transport Temperature:  Refrigerated
Light Protection:  Not Required
Rejection Criteria:  None
Stability:  Room Temperature: 30 day(s)
Refrigerated:  30 day(s)
Frozen (-20 °C): 30 day(s)

Method:  High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT:  Monday-Sunday 7 days (after set-up)
CPT Code:  83789

<table>
<thead>
<tr>
<th>Compound Name / Alias</th>
<th>Units</th>
<th>RL</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lurasidone</td>
<td>ng/mL</td>
<td>2.5</td>
<td>Following single dose administration of 40 mg and 80 mg, the mean Cmax values in serum were approximately 54 and 64 ng/mL, respectively. Following steady-state administration of 40 mg and 80 mg, the mean Cmax values in serum were approximately 48 and 79 ng/mL, respectively. Peak serum concentrations and absorption occur in approximately 1 to 3 hours. Steady-state concentrations are reached within 7 days of initiation of therapy. The elimination half-life is approximately 18 hours. The white blood cell (WBC) count should be monitored periodically, because agranulocytosis, leukopenia, and neutropenia have been reported during clinical trials. The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.</td>
</tr>
<tr>
<td>Latuda®</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2543SP  Lurasidone, Serum/Plasma  Effective Immediately

Scope of Analysis:  Lurasidone [LC-MS/MS]
Method(s):  High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:  Therapeutic Drug Monitoring
Category:  Antipsychotic

Specimen Requirements:  1 mL Serum or Plasma
Minimum Volume:  0.3 mL
Special Handling:  Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Specimen Container:  Plastic container (preservative-free)
New Tests

Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday-Sunday 7 days (after set-up)
CPT Code: 83789

<table>
<thead>
<tr>
<th>Compound Name / Alias</th>
<th>Units</th>
<th>RL</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lurasidone Latuda®</td>
<td>ng/mL</td>
<td>2.5</td>
<td>Following single dose administration of 40 mg and 80 mg, the mean Cmax values in serum were approximately 54 and 64 ng/mL, respectively. Following steady-state administration of 40 mg and 80 mg, the mean Cmax values in serum were approximately 48 and 79 ng/mL, respectively. Peak serum concentrations and absorption occur in approximately 1 to 3 hours. Steady-state concentrations are reached within 7 days of initiation of therapy. The elimination half-life is approximately 18 hours. The white blood cell (WBC) count should be monitored periodically, because agranulocytosis, leukopenia, and neutropenia have been reported during clinical trials.</td>
</tr>
</tbody>
</table>

8894OF Methadone and Metabolite (Qualitative), Oral Fluids Effective Immediately

Scope of Analysis: EDDP [LC-MS/MS], Methadone [LC-MS/MS]
Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose: Identification by LC-MS/MS
Category: Narcotic Analgesic
Specimen Requirements: 1 mL Oral Fluid
Minimum Volume: 0.7 mL
Special Handling: Use either an OraSure Intercept® or Immunalysis QuantisalTM collection device and follow the manufacturer's directions. It is recommended that samples be submitted in the original collection device. However, pour-off containers will be accepted. Samples are stable up to 3 days at room temperature and should be refrigerated thereafter. DO NOT FREEZE the OraSure Intercept® or Immunalysis QuantisalTM collection devices.
Specimen Container: Oral Fluid collection device
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: None
Stability: Room Temperature: Undetermined
Refrigerated: 21 day(s)
Frozen (-20 °C): Undetermined

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Thursday 2 days (after set-up)
CPT Code: 83788

<table>
<thead>
<tr>
<th>Compound Name / Alias</th>
<th>Units</th>
<th>RL</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methadone Dolophine®</td>
<td>ng/mL</td>
<td>10</td>
<td>Methadone (Dolophine) is a DEA Schedule II narcotic analgesic drug used in the treatment of narcotic (heroin) addiction, and for the treatment of pain.</td>
</tr>
</tbody>
</table>
## New Tests

<table>
<thead>
<tr>
<th>Compound Name / Alias</th>
<th>Units</th>
<th>RL</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>EDDP Methadone Metabolite</td>
<td>ng/mL</td>
<td>10</td>
<td>EDDP is a metabolite of the synthetic opioid drug methadone.</td>
</tr>
</tbody>
</table>

### 2810U Methamphetamine and Metabolite, Urine  
**Effective Immediately**

- **Scope of Analysis:** Amphetamine [LC-MS/MS], Methamphetamine [LC-MS/MS]
- **Method(s):** High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
- **Purpose:** Therapeutic Drug Monitoring
- **Category:** Stimulant, Stimulant, Anorexogenic
- **Specimen Requirements:** 1 mL Urine
- **Minimum Volume:** 0.22 mL
- **Special Handling:** None
- **Specimen Container:** Plastic container (preservative-free)
- **Transport Temperature:** Refrigerated
- **Light Protection:** Not Required
- **Rejection Criteria:** None
- **Stability:** Room Temperature: 16 day(s)  
Refrigerated: 16 day(s)  
Frozen (-20 °C): 16 day(s)

**Method:** High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

- **Set-Up Days / TAT:** Monday-Friday 2nd Shift 3 days (after set-up)
- **CPT Code:** 82145

<table>
<thead>
<tr>
<th>Compound Name / Alias</th>
<th>Units</th>
<th>RL</th>
<th>Reference Comment</th>
</tr>
</thead>
</table>
| Amphetamine | ng/mL | 50 | During the first 24 hours after ingestion of 10 mg:  
500 - 4000 ng/mL.  
This test reports Methamphetamine as the total of the undifferentiated d and l enantiomers. The ratio of these enantiomers is important in determining whether the source of Methamphetamine is from over the counter medications, prescribed medication or controlled substances.  
Call lab for further information on d to l enantiomer ratio determination. |

<table>
<thead>
<tr>
<th>Compound Name / Alias</th>
<th>Units</th>
<th>RL</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methamphetamine Metabolite</td>
<td>ng/mL</td>
<td>50</td>
<td></td>
</tr>
</tbody>
</table>

### 8895OF Opiates (Qualitative), Oral Fluids  
**Effective Immediately**

- **Scope of Analysis:** 6-Monoacetylmorphine - Free [LC-MS/MS], Codeine - Free [LC-MS/MS], Dihydrocodeine - Free [LC-MS/MS], Hydromorphone - Free [LC-MS/MS], Hydrocodone - Free [LC-MS/MS], Hydromorphone - Free [LC-MS/MS], Oxycodone - Free [LC-MS/MS], Oxymorphone - Free [LC-MS/MS], Morphine - Free [LC-MS/MS]
- **Method(s):** High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
- **Purpose:** Identification by LC-MS/MS
- **Category:** Stimulant, Anorexogenic, Narcotic Analgesic
- **Specimen Requirements:** 1 mL Oral Fluid
- **Minimum Volume:** 0.7 mL
- **Special Handling:** Use either an OraSure Intercept® or Immunalysis QuantisalTM collection device and follow the manufacturer's directions. It is recommended that samples be submitted in the original collection device. However, pour-off containers will be accepted. Samples are stable up to 3 days at room temperature and should be refrigerated thereafter. DO NOT FREEZE the OraSure Intercept® or Immunalysis QuantisalTM collection devices.
New Tests

Specimen Container: Oral Fluid collection device
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: None
Stability: Room Temperature: Undetermined
Refrigerated: 21 day(s)
Frozen (-20 °C): Undetermined

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Thursday 2 days (after set-up)
CPT Code: 83788

<table>
<thead>
<tr>
<th>Compound Name / Alias</th>
<th>Units</th>
<th>RL</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Codeine - Free</td>
<td>ng/mL</td>
<td>8.0</td>
<td>Codeine is a DEA Schedule III narcotic analgesic with central nervous system depressant activity.</td>
</tr>
<tr>
<td>Morphine - Free</td>
<td>ng/mL</td>
<td>8.0</td>
<td>Morphine is a DEA Schedule II narcotic analgesic used in the treatment of severe and chronic pain. Morphine is also a metabolite of heroin and codeine, and is subject to abuse and dependence.</td>
</tr>
<tr>
<td>Hydrocodone - Free</td>
<td>ng/mL</td>
<td>8.0</td>
<td>Hydrocodone (Vicodin, Lortab) is a schedule III opioid with narcotic analgesic, and antitussive properties.</td>
</tr>
<tr>
<td>Oxycodone - Free</td>
<td>ng/mL</td>
<td>8.0</td>
<td>Oxycodone (Percodan, Oxycontin) is a DEA Schedule II controlled semi-synthetic opioid and narcotic analgesic. It is used in the treatment of moderate to severe pain and is subject to abuse and dependence.</td>
</tr>
<tr>
<td>Oxydorphone - Free</td>
<td>ng/mL</td>
<td>8.0</td>
<td>Oxydorphone (Opana) is a DEA schedule II semisynthetic opioid analgesic. It is indicated for use in the relief of moderate to severe pain and as a preanesthetic medication. Oxydorphone is an active metabolite of oxycodone.</td>
</tr>
<tr>
<td>Dihydrocodeine - Free</td>
<td>ng/mL</td>
<td>8.0</td>
<td>Dihydrocodeine is a schedule II opioid analgesic. Preparations with small amounts may be schedule III or IV. It is available as a therapeutic agent for oral use and can be formed in vivo as a metabolite of hydrocodeine.</td>
</tr>
</tbody>
</table>

---

8896OF Phencyclidine and Dextromethorphan (Qualitative), Oral Fluids Effective Immediately

Scope of Analysis:
Dextromethorphan [LC-MS/MS], Phencyclidine [LC-MS/MS]

Method(s):
High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Purpose:
Identification by LC-MS/MS

Category:
Antitussive, Hallucinogen

Specimen Requirements:
1 mL Oral Fluid

Minimum Volume:
0.7 mL

Special Handling:
Use either an OraSure Intercept® or Immunalysis QuantisalTM collection device and follow the manufacturer’s directions. It is recommended that samples be submitted in the original collection device. However, pour-off containers will be accepted. Samples are stable up to 3 days at room temperature and...
New Tests

should be refrigerated thereafter. DO NOT FREEZE the OraSure Intercept® or Immulanalysis QuantisalTM collection devices.

Specimen Container: Oral Fluid collection device
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: None

Stability:
Room Temperature: Undetermined
Refrigerated: 21 day(s)
Frozen (-20 °C): Undetermined

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Thursday 2 days (after set-up)
CPT Code: 83788

<table>
<thead>
<tr>
<th>Compound Name / Alias</th>
<th>Units</th>
<th>RL</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phencyclidine</td>
<td>ng/mL</td>
<td>4.0</td>
<td>Phencyclidine (PCP) is a DEA Schedule II controlled dangerous hallucinogenic drug. It is subject to abuse and dependence.</td>
</tr>
<tr>
<td>Angel Dust; PCP; Sherm</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dextromethorphan</td>
<td>ng/mL</td>
<td>100</td>
<td>Dextromethorphan (DXM) is an over the counter antitussive. When taken in excess it causes intoxication and dissociative effects, and is subject to abuse and dependence. This test does not distinguish between dextromethorphan and its isomer levomethorphan.</td>
</tr>
</tbody>
</table>

Vilazodone, Blood

Effective Immediately

Scope of Analysis: Vilazodone (LC-MS/MS)
Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose: Therapeutic Drug Monitoring and Postmortem Forensic Analysis
Category: Antidepressant

Specimen Requirements: 1 mL Blood
Minimum Volume: 0.3 mL
Special Handling: None
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate)
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: None

Stability:
Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday-Sunday 7 days (after set-up)
CPT Code: 83789

<table>
<thead>
<tr>
<th>Compound Name / Alias</th>
<th>Units</th>
<th>RL</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vilazodone</td>
<td>ng/mL</td>
<td>5.0</td>
<td>A single 20 mg oral dose resulted in a mean peak plasma concentration of 43 ng/mL (range, 28 - 63 ng/mL) at 5 hours after administration. A single 40 mg oral dose under fed conditions produced a mean peak plasma concentration of 90 ng/mL (range, 60 - 120 ng/mL). After dosing with 40 mg daily under fed conditions, the mean peak steady-state serum concentration was 156 ng/mL. The blood to plasma ratio for this drug is unknown.</td>
</tr>
<tr>
<td>Viibryd®</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### New Tests

<table>
<thead>
<tr>
<th>Test Code</th>
<th>Test Name</th>
<th>Effective Immediately</th>
</tr>
</thead>
<tbody>
<tr>
<td>4790SP</td>
<td>Vilazodone, Serum/Plasma</td>
<td>Effective Immediately</td>
</tr>
</tbody>
</table>

**Scope of Analysis:** Vilazodone [LC-MS/MS]  
**Method(s):** High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)  
**Purpose:** Therapeutic Drug Monitoring and Postmortem Forensic Analysis  
**Category:** Antidepressant  
**Specimen Requirements:**  
- Minimum Volume: 1 mL Serum or Plasma  
- Special Handling:  
  - Serum: Collect sample in Red top tube  
  - Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.  
**Specimen Container:** Plastic container (preservative-free)  
**Transport Temperature:** Refrigerated  
**Light Protection:** Not Required  
**Rejection Criteria:** Polymer gel separation tube (SST or PST).  
**Stability:**  
- Room Temperature: 30 day(s)  
- Refrigerated: 30 day(s)  
- Frozen (-20 °C): 30 day(s)  

**Method:** High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)  
**Set-Up Days / TAT:** Monday-Sunday 7 days (after set-up)  
**CPT Code:** 83789  

<table>
<thead>
<tr>
<th>Compound Name / Alias</th>
<th>Units</th>
<th>RL</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vilazodone</td>
<td>ng/mL</td>
<td>5.0</td>
<td></td>
</tr>
<tr>
<td>Viibryd®</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

A single 20 mg oral dose resulted in a mean peak plasma concentration of 43 ng/mL (range, 28 - 63 ng/mL) at 5 hours after administration.  
A single 40 mg oral dose under fed conditions produced a mean peak plasma concentration of 90 ng/mL (range, 60 - 120 ng/mL).  
After dosing with 40 mg daily under fed conditions, the mean peak steady-state serum concentration was 156 ng/mL.
Test Changes

2526B  Leflunomide as Metabolite, Blood

Summary of Changes: Specimen Requirements were changed.

- Specimen Requirements: 1 mL Blood
- Transport Temperature: Refrigerated
- Specimen Container: NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test.
- Light Protection: Not Required
- Special Handling: None
- Rejection Criteria: None

4030B  Pyridine, Blood

Summary of Changes: Units were changed.

Scope of Analysis: GC (82491): Pyridine

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pyridine</td>
<td>mcg/mL</td>
<td>No reference data available.</td>
</tr>
</tbody>
</table>

4030SP  Pyridine, Serum/Plasma

Summary of Changes: Units were changed.

Scope of Analysis: GC (82491): Pyridine

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pyridine</td>
<td>mcg/mL</td>
<td>No reference data available.</td>
</tr>
</tbody>
</table>

4030U  Pyridine, Urine

Summary of Changes: Units were changed.

Scope of Analysis: GC (82491): Pyridine

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pyridine</td>
<td>mcg/mL</td>
<td>No reference data available.</td>
</tr>
</tbody>
</table>
## Discontinued Tests

<table>
<thead>
<tr>
<th>Test Code</th>
<th>Test Name</th>
<th>Alternative Test</th>
</tr>
</thead>
<tbody>
<tr>
<td>0478FL</td>
<td>Astemizole and Metabolite, Fluid</td>
<td>No Alternate Tests Available</td>
</tr>
<tr>
<td>0478SP</td>
<td>Astemizole and Metabolite, Serum/Plasma</td>
<td>No Alternate Tests Available</td>
</tr>
<tr>
<td>0478TI</td>
<td>Astemizole and Metabolite, Tissue</td>
<td>No Alternate Tests Available</td>
</tr>
<tr>
<td>1140SP</td>
<td>Chloroquine, Serum/Plasma</td>
<td>1140P - Chloroquine, Plasma</td>
</tr>
<tr>
<td>8602B</td>
<td>Methamphetamine and Metabolite, Blood</td>
<td>2810B - Methamphetamine and Metabolite, Blood</td>
</tr>
<tr>
<td>8602FL</td>
<td>Methamphetamine and Metabolite, Fluid</td>
<td>2810FL - Methamphetamine and Metabolite, Fluid</td>
</tr>
<tr>
<td>8602SP</td>
<td>Methamphetamine and Metabolite, Serum/Plasma</td>
<td>2810SP - Methamphetamine and Metabolite, Serum/Plasma</td>
</tr>
<tr>
<td>8602TI</td>
<td>Methamphetamine and Metabolite, Tissue</td>
<td>2810TI - Methamphetamine and Metabolite, Tissue</td>
</tr>
<tr>
<td>8602U</td>
<td>Methamphetamine and Metabolite, Urine</td>
<td>2810U - Methamphetamine and Metabolite, Urine</td>
</tr>
</tbody>
</table>